Castleark Management LLC Takes $6 Million Position in Krystal Biotech, Inc. $KRYS

Castleark Management LLC bought a new position in Krystal Biotech, Inc. (NASDAQ:KRYS) during the 2nd quarter, Holdings Channel reports. The fund bought 16,150 shares of the company’s stock, valued at approximately $6,002,000.

A number of other large investors have also made changes to their positions in KRYS. Silvant Capital Management LLC bought a new position in Krystal Biotech during the second quarter worth about $30,000. Western Wealth Management LLC bought a new position in shares of Krystal Biotech in the first quarter worth about $34,000. Greenline Wealth Management LLC bought a new stake in shares of Krystal Biotech during the fourth quarter valued at approximately $34,000. Danske Bank A S acquired a new stake in shares of Krystal Biotech in the third quarter valued at approximately $35,000. Finally, UMB Bank n.a. raised its position in shares of Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after acquiring an additional 37 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Stock Up 4.2%

NASDAQ KRYS opened at $356.19 on Wednesday. The firm’s 50 day moving average is $348.02 and its 200-day moving average is $302.59. The company has a market capitalization of $10.54 billion, a PE ratio of 44.64 and a beta of 0.53. Krystal Biotech, Inc. has a 12-month low of $136.73 and a 12-month high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, topping the consensus estimate of $1.70 by $0.09. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The business had revenue of $119.22 million during the quarter, compared to analysts’ expectations of $120.93 million. As a group, sell-side analysts expect that Krystal Biotech, Inc. will post 7.68 EPS for the current year.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the sale, the insider owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the transaction, the executive vice president directly owned 1,000 shares of the company’s stock, valued at $347,270. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 51,000 shares of company stock worth $16,278,020 in the last three months. Insiders own 13.10% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on KRYS shares. TD Cowen boosted their price target on shares of Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Bank of America lifted their price objective on Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Evercore reaffirmed an “outperform” rating and issued a $300.00 price target on shares of Krystal Biotech in a research note on Tuesday, May 5th. Citigroup upped their price target on shares of Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Finally, Chardan Capital raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $365.40.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.